JWC_JWCI-16-001

A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer

The purpose of this study is to try to determine the maximum safe dose of afatinib that can be administered to people with brain cancer. Other purposes of this study are to:

find out what effects (good and bad) afatinib has;
see how much drug gets into the body by collecting blood and cerebrospinal fluid for use in pharmacokinetic (PK) studies;
learn more about how afatinib might affect the growth of cancer cells;
look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug).
Phase I
NCT02423525
Cancer
Brain
Santosh Kesari, M.D.
John Wayne Cancer Institute
Hanh Nguyen Thuy
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)